Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease
Identifieur interne : 003691 ( Main/Curation ); précédent : 003690; suivant : 003692Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease
Auteurs : Jean-Louis Montastruc [France] ; Karine Desboeuf [France] ; Maryse Lapeyre-Mestre [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; Christine Brefel-Courbon [France]Source :
- Movement Disorders [ 0885-3185 ] ; 2001-05.
Descripteurs français
- Pascal (Inist)
- Wicri :
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (therapeutic use), Antiparkinson agent, Bromocriptine, Bromocriptine (administration & dosage), Bromocriptine (therapeutic use), Chemotherapy, Drug Therapy, Combination, Ergot derivatives, Female, Follow-Up Studies, France (epidemiology), Human, Humans, Levodopa, Levodopa (administration & dosage), Levodopa (therapeutic use), Long term, Male, Middle Aged, Mortality, Mortality (trends), Parkinson Disease (drug therapy), Parkinson Disease (mortality), Parkinson disease, Parkinson's disease, Prospective Studies, Treatment, Treatment Outcome, bromocriptine, levodopa, mortality.
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Bromocriptine, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Bromocriptine, Levodopa.
- geographic , epidemiology : France.
- drug therapy : Parkinson Disease.
- mortality : Parkinson Disease.
- trends : Mortality.
- Aged, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prospective Studies, Treatment Outcome.
Abstract
The present paper compares, in terms of mortality, two treatment regimens for Parkinson's disease (PD), i.e., bromocriptine later combined with levodopa versus levodopa only. Between 1982 and 1989, 60 PD patients (29 treated with levodopa alone [group D] and 31 receiving first bromocriptine followed by an association of bromocriptine + levodopa [group B/D]) were recruited. Data were updated in January 2000. Survival functions were estimated using Kaplan Meier product‐limit method and comparison between the two groups with the log‐rank test. Mortality was also compared with that of the general French population using standardized mortality ratios (SMRs). The mean duration of follow‐up was 10.3 ± 3.0 years. Seventeen patients died during the follow‐up: nine in the group B/D and eight in the group D. The probability of survival at 10 years was 79.0% [95% confidence interval [CI]: 71.4–86.6] in group B/D and 72.9% [95% CI: 63.3–82.6] in group D. In comparison with the general French population, SMRs were not statistically different from 1, in the whole sample of PD patients (1.21, 95 % CI [0.71–1.95]), in group D (0.98 [0.42–1.93]), or in group B/D (1.53 [0.70–2.92]). In this population, we were unable to find any favourable effect of an early use of bromocriptine on mortality in PD in comparison with levodopa alone. © 2001 Movement Disorder Society.
Url:
DOI: 10.1002/mds.1093
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000808
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :000808
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000F02
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :003C69
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001203
- to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :000235
- to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001048
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :003E04
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001251
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001210
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001210
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000191
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :000191
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000191
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :003B34
Links to Exploration step
ISTEX:DB129378E12554A8F9378511E8F16E3C6FB4CCFDLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease</title><author><name sortKey="Montastruc, Jean Ouis" sort="Montastruc, Jean Ouis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name></author><author><name sortKey="Desboeuf, Karine" sort="Desboeuf, Karine" uniqKey="Desboeuf K" first="Karine" last="Desboeuf">Karine Desboeuf</name></author><author><name sortKey="Lapeyre Estre, Maryse" sort="Lapeyre Estre, Maryse" uniqKey="Lapeyre Estre M" first="Maryse" last="Lapeyre-Mestre">Maryse Lapeyre-Mestre</name></author><author><name sortKey="Senard, Jean Ichel" sort="Senard, Jean Ichel" uniqKey="Senard J" first="Jean-Michel" last="Senard">Jean-Michel Senard</name></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></author><author><name sortKey="Brefel Ourbon, Christine" sort="Brefel Ourbon, Christine" uniqKey="Brefel Ourbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:DB129378E12554A8F9378511E8F16E3C6FB4CCFD</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1002/mds.1093</idno><idno type="url">https://api.istex.fr/document/DB129378E12554A8F9378511E8F16E3C6FB4CCFD/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000808</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000808</idno><idno type="wicri:Area/Istex/Curation">000808</idno><idno type="wicri:Area/Istex/Checkpoint">000F02</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000F02</idno><idno type="wicri:doubleKey">0885-3185:2001:Montastruc J:long:term:mortality</idno><idno type="wicri:Area/Main/Merge">003C69</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:01-0377069</idno><idno type="wicri:Area/PascalFrancis/Corpus">001203</idno><idno type="wicri:Area/PascalFrancis/Curation">000235</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001048</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001048</idno><idno type="wicri:doubleKey">0885-3185:2001:Montastruc J:long:term:mortality</idno><idno type="wicri:Area/Main/Merge">003E04</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:11391747</idno><idno type="wicri:Area/PubMed/Corpus">001251</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001251</idno><idno type="wicri:Area/PubMed/Curation">001210</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001210</idno><idno type="wicri:Area/PubMed/Checkpoint">001210</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001210</idno><idno type="wicri:Area/Ncbi/Merge">000191</idno><idno type="wicri:Area/Ncbi/Curation">000191</idno><idno type="wicri:Area/Ncbi/Checkpoint">000191</idno><idno type="wicri:doubleKey">0885-3185:2001:Montastruc J:long:term:mortality</idno><idno type="wicri:Area/Main/Merge">003B34</idno><idno type="wicri:Area/Main/Curation">003691</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease</title><author><name sortKey="Montastruc, Jean Ouis" sort="Montastruc, Jean Ouis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</wicri:regionArea><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion></affiliation><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Service de Pharmacologie Clinique, Faculté de Médecine, 37 allées Jules‐Guesde, 31073 Toulouse Cedex</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Desboeuf, Karine" sort="Desboeuf, Karine" uniqKey="Desboeuf K" first="Karine" last="Desboeuf">Karine Desboeuf</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</wicri:regionArea><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion></affiliation></author><author><name sortKey="Lapeyre Estre, Maryse" sort="Lapeyre Estre, Maryse" uniqKey="Lapeyre Estre M" first="Maryse" last="Lapeyre-Mestre">Maryse Lapeyre-Mestre</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</wicri:regionArea><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion></affiliation></author><author><name sortKey="Senard, Jean Ichel" sort="Senard, Jean Ichel" uniqKey="Senard J" first="Jean-Michel" last="Senard">Jean-Michel Senard</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</wicri:regionArea><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</wicri:regionArea><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion></affiliation></author><author><name sortKey="Brefel Ourbon, Christine" sort="Brefel Ourbon, Christine" uniqKey="Brefel Ourbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</wicri:regionArea><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2001-05">2001-05</date><biblScope unit="volume">16</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="511">511</biblScope><biblScope unit="page" to="514">514</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">DB129378E12554A8F9378511E8F16E3C6FB4CCFD</idno><idno type="DOI">10.1002/mds.1093</idno><idno type="ArticleID">MDS1093</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Antiparkinson agent</term><term>Bromocriptine</term><term>Bromocriptine (administration & dosage)</term><term>Bromocriptine (therapeutic use)</term><term>Chemotherapy</term><term>Drug Therapy, Combination</term><term>Ergot derivatives</term><term>Female</term><term>Follow-Up Studies</term><term>France (epidemiology)</term><term>Human</term><term>Humans</term><term>Levodopa</term><term>Levodopa (administration & dosage)</term><term>Levodopa (therapeutic use)</term><term>Long term</term><term>Male</term><term>Middle Aged</term><term>Mortality</term><term>Mortality (trends)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (mortality)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Prospective Studies</term><term>Treatment</term><term>Treatment Outcome</term><term>bromocriptine</term><term>levodopa</term><term>mortality</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Bromocriptine</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Bromocriptine</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>France</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Mortality</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Drug Therapy, Combination</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term><term>Treatment Outcome</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Antiparkinsonien</term><term>Bromocriptine</term><term>Chimiothérapie</term><term>Ergot dérivé</term><term>Homme</term><term>Long terme</term><term>Lévodopa</term><term>Mortalité</term><term>Parkinson maladie</term><term>Traitement</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>France</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term><term>Mortalité</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The present paper compares, in terms of mortality, two treatment regimens for Parkinson's disease (PD), i.e., bromocriptine later combined with levodopa versus levodopa only. Between 1982 and 1989, 60 PD patients (29 treated with levodopa alone [group D] and 31 receiving first bromocriptine followed by an association of bromocriptine + levodopa [group B/D]) were recruited. Data were updated in January 2000. Survival functions were estimated using Kaplan Meier product‐limit method and comparison between the two groups with the log‐rank test. Mortality was also compared with that of the general French population using standardized mortality ratios (SMRs). The mean duration of follow‐up was 10.3 ± 3.0 years. Seventeen patients died during the follow‐up: nine in the group B/D and eight in the group D. The probability of survival at 10 years was 79.0% [95% confidence interval [CI]: 71.4–86.6] in group B/D and 72.9% [95% CI: 63.3–82.6] in group D. In comparison with the general French population, SMRs were not statistically different from 1, in the whole sample of PD patients (1.21, 95 % CI [0.71–1.95]), in group D (0.98 [0.42–1.93]), or in group B/D (1.53 [0.70–2.92]). In this population, we were unable to find any favourable effect of an early use of bromocriptine on mortality in PD in comparison with levodopa alone. © 2001 Movement Disorder Society.</div></front></TEI><double idat="0885-3185:2001:Montastruc J:long:term:mortality"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Long-term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease</title><author><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</s1><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion><wicri:noRegion>Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion></affiliation></author><author><name sortKey="Desboeuf, Karine" sort="Desboeuf, Karine" uniqKey="Desboeuf K" first="Karine" last="Desboeuf">Karine Desboeuf</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</s1><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion><wicri:noRegion>Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion></affiliation></author><author><name sortKey="Lapeyre Mestre, Maryse" sort="Lapeyre Mestre, Maryse" uniqKey="Lapeyre Mestre M" first="Maryse" last="Lapeyre-Mestre">Maryse Lapeyre-Mestre</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</s1><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion><wicri:noRegion>Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion></affiliation></author><author><name sortKey="Senard, Jean Michel" sort="Senard, Jean Michel" uniqKey="Senard J" first="Jean-Michel" last="Senard">Jean-Michel Senard</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</s1><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion><wicri:noRegion>Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</s1><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion><wicri:noRegion>Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion></affiliation></author><author><name sortKey="Brefel Courbon, Christine" sort="Brefel Courbon, Christine" uniqKey="Brefel Courbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</s1><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion><wicri:noRegion>Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">01-0377069</idno><date when="2001">2001</date><idno type="stanalyst">PASCAL 01-0377069 INIST</idno><idno type="RBID">Pascal:01-0377069</idno><idno type="wicri:Area/PascalFrancis/Corpus">001203</idno><idno type="wicri:Area/PascalFrancis/Curation">000235</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001048</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001048</idno><idno type="wicri:doubleKey">0885-3185:2001:Montastruc J:long:term:mortality</idno><idno type="wicri:Area/Main/Merge">003E04</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Long-term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease</title><author><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</s1><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion><wicri:noRegion>Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion></affiliation></author><author><name sortKey="Desboeuf, Karine" sort="Desboeuf, Karine" uniqKey="Desboeuf K" first="Karine" last="Desboeuf">Karine Desboeuf</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</s1><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion><wicri:noRegion>Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion></affiliation></author><author><name sortKey="Lapeyre Mestre, Maryse" sort="Lapeyre Mestre, Maryse" uniqKey="Lapeyre Mestre M" first="Maryse" last="Lapeyre-Mestre">Maryse Lapeyre-Mestre</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</s1><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion><wicri:noRegion>Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion></affiliation></author><author><name sortKey="Senard, Jean Michel" sort="Senard, Jean Michel" uniqKey="Senard J" first="Jean-Michel" last="Senard">Jean-Michel Senard</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</s1><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion><wicri:noRegion>Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</s1><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion><wicri:noRegion>Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion></affiliation></author><author><name sortKey="Brefel Courbon, Christine" sort="Brefel Courbon, Christine" uniqKey="Brefel Courbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</s1><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion><wicri:noRegion>Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2001">2001</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term><term>Bromocriptine</term><term>Chemotherapy</term><term>Ergot derivatives</term><term>Human</term><term>Levodopa</term><term>Long term</term><term>Mortality</term><term>Parkinson disease</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term><term>Bromocriptine</term><term>Lévodopa</term><term>Antiparkinsonien</term><term>Chimiothérapie</term><term>Mortalité</term><term>Traitement</term><term>Homme</term><term>Long terme</term><term>Ergot dérivé</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Mortalité</term><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The present paper compares, in terms of mortality, two treatment regimens for Parkinson's disease (PD), i.e., bromocriptine later combined with levodopa versus levodopa only. Between 1982 and 1989, 60 PD patients (29 treated with levodopa alone [group D] and 31 receiving first bromocriptine followed by an association of bromocriptine + levodopa [group B/D]) were recruited. Data were updated in January 2000. Survival functions were estimated using Kaplan Meier product-limit method and comparison between the two groups with the log-rank test. Mortality was also compared with that of the general French population using standardized mortality ratios (SMRs). The mean duration of follow-up was 10.3 ± 3.0 years. Seventeen patients died during the follow-up: nine in the group BID and eight in the group D. The probability of survival at 10 years was 79.0% [95% confidence interval [CI]: 71.4-86.6] in group B/D and 72.9% [95% CI: 63.3-82.6] in group D. In comparison with the general French population, SMRs were not statistically different from 1, in the whole sample of PD patients (1.21, 95 % CI [0.71-1.95]), in group D (0.98 [0.42-1.93]), or in group B/D (1.53 [0.70-2.92]). In this population, we were unable to find any favourable effect of an early use of bromocriptine on mortality in PD in comparison with levodopa alone.</div></front></TEI></INIST><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease</title><author><name sortKey="Montastruc, Jean Ouis" sort="Montastruc, Jean Ouis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name></author><author><name sortKey="Desboeuf, Karine" sort="Desboeuf, Karine" uniqKey="Desboeuf K" first="Karine" last="Desboeuf">Karine Desboeuf</name></author><author><name sortKey="Lapeyre Estre, Maryse" sort="Lapeyre Estre, Maryse" uniqKey="Lapeyre Estre M" first="Maryse" last="Lapeyre-Mestre">Maryse Lapeyre-Mestre</name></author><author><name sortKey="Senard, Jean Ichel" sort="Senard, Jean Ichel" uniqKey="Senard J" first="Jean-Michel" last="Senard">Jean-Michel Senard</name></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></author><author><name sortKey="Brefel Ourbon, Christine" sort="Brefel Ourbon, Christine" uniqKey="Brefel Ourbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:DB129378E12554A8F9378511E8F16E3C6FB4CCFD</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1002/mds.1093</idno><idno type="url">https://api.istex.fr/document/DB129378E12554A8F9378511E8F16E3C6FB4CCFD/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000808</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000808</idno><idno type="wicri:Area/Istex/Curation">000808</idno><idno type="wicri:Area/Istex/Checkpoint">000F02</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000F02</idno><idno type="wicri:doubleKey">0885-3185:2001:Montastruc J:long:term:mortality</idno><idno type="wicri:Area/Main/Merge">003C69</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease</title><author><name sortKey="Montastruc, Jean Ouis" sort="Montastruc, Jean Ouis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</wicri:regionArea><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion></affiliation><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Service de Pharmacologie Clinique, Faculté de Médecine, 37 allées Jules‐Guesde, 31073 Toulouse Cedex</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Desboeuf, Karine" sort="Desboeuf, Karine" uniqKey="Desboeuf K" first="Karine" last="Desboeuf">Karine Desboeuf</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</wicri:regionArea><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion></affiliation></author><author><name sortKey="Lapeyre Estre, Maryse" sort="Lapeyre Estre, Maryse" uniqKey="Lapeyre Estre M" first="Maryse" last="Lapeyre-Mestre">Maryse Lapeyre-Mestre</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</wicri:regionArea><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion></affiliation></author><author><name sortKey="Senard, Jean Ichel" sort="Senard, Jean Ichel" uniqKey="Senard J" first="Jean-Michel" last="Senard">Jean-Michel Senard</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</wicri:regionArea><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</wicri:regionArea><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion></affiliation></author><author><name sortKey="Brefel Ourbon, Christine" sort="Brefel Ourbon, Christine" uniqKey="Brefel Ourbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</wicri:regionArea><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2001-05">2001-05</date><biblScope unit="volume">16</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="511">511</biblScope><biblScope unit="page" to="514">514</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">DB129378E12554A8F9378511E8F16E3C6FB4CCFD</idno><idno type="DOI">10.1002/mds.1093</idno><idno type="ArticleID">MDS1093</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>bromocriptine</term><term>levodopa</term><term>mortality</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The present paper compares, in terms of mortality, two treatment regimens for Parkinson's disease (PD), i.e., bromocriptine later combined with levodopa versus levodopa only. Between 1982 and 1989, 60 PD patients (29 treated with levodopa alone [group D] and 31 receiving first bromocriptine followed by an association of bromocriptine + levodopa [group B/D]) were recruited. Data were updated in January 2000. Survival functions were estimated using Kaplan Meier product‐limit method and comparison between the two groups with the log‐rank test. Mortality was also compared with that of the general French population using standardized mortality ratios (SMRs). The mean duration of follow‐up was 10.3 ± 3.0 years. Seventeen patients died during the follow‐up: nine in the group B/D and eight in the group D. The probability of survival at 10 years was 79.0% [95% confidence interval [CI]: 71.4–86.6] in group B/D and 72.9% [95% CI: 63.3–82.6] in group D. In comparison with the general French population, SMRs were not statistically different from 1, in the whole sample of PD patients (1.21, 95 % CI [0.71–1.95]), in group D (0.98 [0.42–1.93]), or in group B/D (1.53 [0.70–2.92]). In this population, we were unable to find any favourable effect of an early use of bromocriptine on mortality in PD in comparison with levodopa alone. © 2001 Movement Disorder Society.</div></front></TEI></ISTEX><PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long-term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease.</title><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J L" last="Montastruc">J L Montastruc</name><affiliation wicri:level="1"><nlm:affiliation>Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse, France. montastruc@cict.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</wicri:regionArea><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion></affiliation></author><author><name sortKey="Desboeuf, K" sort="Desboeuf, K" uniqKey="Desboeuf K" first="K" last="Desboeuf">K. Desboeuf</name></author><author><name sortKey="Lapeyre Mestre, M" sort="Lapeyre Mestre, M" uniqKey="Lapeyre Mestre M" first="M" last="Lapeyre-Mestre">M. Lapeyre-Mestre</name></author><author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J M" last="Senard">J M Senard</name></author><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name></author><author><name sortKey="Brefel Courbon, C" sort="Brefel Courbon, C" uniqKey="Brefel Courbon C" first="C" last="Brefel-Courbon">C. Brefel-Courbon</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2001">2001</date><idno type="RBID">pubmed:11391747</idno><idno type="pmid">11391747</idno><idno type="wicri:Area/PubMed/Corpus">001251</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001251</idno><idno type="wicri:Area/PubMed/Curation">001210</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001210</idno><idno type="wicri:Area/PubMed/Checkpoint">001210</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001210</idno><idno type="wicri:Area/Ncbi/Merge">000191</idno><idno type="wicri:Area/Ncbi/Curation">000191</idno><idno type="wicri:Area/Ncbi/Checkpoint">000191</idno><idno type="wicri:doubleKey">0885-3185:2001:Montastruc J:long:term:mortality</idno><idno type="wicri:Area/Main/Merge">003B34</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Long-term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease.</title><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J L" last="Montastruc">J L Montastruc</name><affiliation wicri:level="1"><nlm:affiliation>Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse, France. montastruc@cict.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</wicri:regionArea><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion><wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion></affiliation></author><author><name sortKey="Desboeuf, K" sort="Desboeuf, K" uniqKey="Desboeuf K" first="K" last="Desboeuf">K. Desboeuf</name></author><author><name sortKey="Lapeyre Mestre, M" sort="Lapeyre Mestre, M" uniqKey="Lapeyre Mestre M" first="M" last="Lapeyre-Mestre">M. Lapeyre-Mestre</name></author><author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J M" last="Senard">J M Senard</name></author><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name></author><author><name sortKey="Brefel Courbon, C" sort="Brefel Courbon, C" uniqKey="Brefel Courbon C" first="C" last="Brefel-Courbon">C. Brefel-Courbon</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2001" type="published">2001</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Bromocriptine (administration & dosage)</term><term>Bromocriptine (therapeutic use)</term><term>Drug Therapy, Combination</term><term>Female</term><term>Follow-Up Studies</term><term>France (epidemiology)</term><term>Humans</term><term>Levodopa (administration & dosage)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Mortality (trends)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (mortality)</term><term>Prospective Studies</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Bromocriptine</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Bromocriptine</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>France</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Mortality</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Drug Therapy, Combination</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term><term>Treatment Outcome</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>France</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The present paper compares, in terms of mortality, two treatment regimens for Parkinson's disease (PD), i.e., bromocriptine later combined with levodopa versus levodopa only. Between 1982 and 1989, 60 PD patients (29 treated with levodopa alone [group D] and 31 receiving first bromocriptine followed by an association of bromocriptine + levodopa [group B/D]) were recruited. Data were updated in January 2000. Survival functions were estimated using Kaplan Meier product-limit method and comparison between the two groups with the log-rank test. Mortality was also compared with that of the general French population using standardized mortality ratios (SMRs). The mean duration of follow-up was 10.3 +/- 3.0 years. Seventeen patients died during the follow-up: nine in the group B/D and eight in the group D. The probability of survival at 10 years was 79.0% [95% confidence interval [CI]: 71.4-86.6] in group B/D and 72.9% [95% CI: 63.3-82.6] in group D. In comparison with the general French population, SMRs were not statistically different from 1, in the whole sample of PD patients (1.21, 95 % CI [0.71-1.95]), in group D (0.98 [0.42-1.93]), or in group B/D (1.53 [0.70-2.92]). In this population, we were unable to find any favourable effect of an early use of bromocriptine on mortality in PD in comparison with levodopa alone.</div></front></TEI></PubMed></double></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003691 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 003691 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Main
|étape= Curation
|type= RBID
|clé= ISTEX:DB129378E12554A8F9378511E8F16E3C6FB4CCFD
|texte= Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease
}}
| This area was generated with Dilib version V0.6.29. |  |